{'52WeekChange': -0.15944988,
 'SandP52WeekChange': None,
 'address1': '2 Gansevoort Street',
 'address2': '9th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 18.07,
 'askSize': 2900,
 'averageDailyVolume10Day': 20150,
 'averageVolume': 23777,
 'averageVolume10days': 20150,
 'beta': 2.170868,
 'beta3Year': None,
 'bid': 17.8,
 'bidSize': 900,
 'bookValue': 0.474,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': None,
 'dayHigh': 18.18,
 'dayLow': 18.0236,
 'dividendRate': 2.34,
 'dividendYield': 0.1289,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -15.635,
 'enterpriseToRevenue': 35.022,
 'enterpriseValue': 1508392448,
 'exDividendDate': 1576108800,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 18.173971,
 'fiftyTwoWeekHigh': 21.95,
 'fiftyTwoWeekLow': 12,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 59169413,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 93,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.04087,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/fortressbiotech.com',
 'longBusinessSummary': 'Fortress Biotech, Inc. develops and commercializes '
                        'pharmaceutical and biotechnology products. It markets '
                        'dermatology products, such as Targadox for acne; '
                        'Exelderm cream for ringworm and jock itch symptoms; '
                        'Ceracade for dry skin conditions; Luxamend for '
                        'dressing and managing wounds; Ala-Scalp and Triderm, '
                        'which are used for the inflammatory and pruritic '
                        'manifestations of corticosteroid-responsive '
                        'dermatoses; and Ala-Quin, an antibacterial and '
                        'antifungal cream. The company also develops MB-107, a '
                        'gene therapy for X-linked severe combined '
                        'immunodeficiency; CAEL-101, a Phase Ia/Ib trial that '
                        'reduces amyloid deposits in the tissues and organs; '
                        'CD123 chimeric antigen receptor engineered T-cell '
                        '(CAR T) program for acute myeloid leukemia; CD20 CAR '
                        'T program for B cell non-Hodgkin lymphoma; and CS1 '
                        'CAR T for multiple myeloma and light chain '
                        'amyloidosis. In addition, it develops MB-101 for '
                        'Glioblastoma (GBM); MB-103 for GBM, and breast cancer '
                        'and brain metastases; MB-105 for prostate and '
                        'pancreatic cancers; intravenous Tramadol for '
                        'post-operative pain; CK-101, a Phase I/II clinical '
                        'trial for treating patients with EGFR '
                        'mutation-positive non-small cell lung cancer; CK-301, '
                        'a Phase I clinical trial for metastatic cancer; '
                        'Triplex, a Phase I study recombinant modified '
                        'vaccinia ankara viral vector vaccine; ConVax, a '
                        'recombinant modified vaccinia ankara viral vector '
                        'vaccine; CEVA-101 for traumatic brain injury; CEVA-D, '
                        'a bioreactor device that enhances the '
                        'anti-inflammatory potency of bone marrow-derived '
                        'cells; Tamid-001, a gene therapy for '
                        'mucopolysaccharidosis type I disorder; CNDO-109, a '
                        'lysate that activates donor natural killer cells; and '
                        'methazalomide products. The company has collaboration '
                        'arrangements with some universities, research '
                        'institutes, and pharmaceutical companies. The company '
                        'was formerly known as Coronado Biosciences, Inc. and '
                        'changed its name to Fortress Biotech, Inc. in April '
                        '2015. Fortress Biotech, Inc. was founded in 2006 and '
                        'is based in New York, New York.',
 'longName': 'Fortress Biotech, Inc.',
 'market': 'us_market',
 'marketCap': 96997408,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_61731337',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -53722000,
 'nextFiscalYearEnd': 1640908800,
 'open': 18.18,
 'openInterest': None,
 'payoutRatio': None,
 'pegRatio': None,
 'phone': '781 652 4500',
 'previousClose': 18.15,
 'priceHint': 2,
 'priceToBook': 38.12236,
 'priceToSalesTrailing12Months': 2.2520876,
 'profitMargins': -1.24732,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.18,
 'regularMarketDayLow': 18.0236,
 'regularMarketOpen': 18.18,
 'regularMarketPreviousClose': 18.15,
 'regularMarketPrice': 18.18,
 'regularMarketVolume': 6234,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 56679500,
 'sharesPercentSharesOut': None,
 'sharesShort': None,
 'sharesShortPreviousMonthDate': None,
 'sharesShortPriorMonth': None,
 'shortName': 'Fortress Biotech, Inc. - 9.375%',
 'shortPercentOfFloat': None,
 'shortRatio': None,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'FBIOP',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.919,
 'twoHundredDayAverage': 18.587467,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '519aaf33-2bcc-3da3-a8c8-568c9fd45fac',
 'volume': 6234,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.fortressbiotech.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10014'}